KZIA
Kazia Therapeutics Limited
NASDAQ · Healthcare · Biotechnology · AU
$12.31
+1.23%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.5M | 42.0K | 2.3M | 555.00 | 10.0K |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | 2.5M | 42.0K | 2.3M | 555.00 | 10.0K |
| Operating Expenses | |||||
| R&D Expense | 25.2M | 7.3M | 17.4M | 15.6M | 20.2M |
| SG&A Expense | 26.0M | 8.7M | 13.6M | 8.6M | 5.2M |
| General & Admin Expense | 14.1M | 8.7M | 13.6M | 8.6M | 5.1M |
| Selling & Marketing Expense | — | — | — | — | 127.0K |
| Other Expenses | — | (1.8M) | (173.0K) | (22.6K) | — |
| Total Operating Expenses | 51.2M | 14.3M | 30.8M | 24.1M | 25.4M |
| Cost and Expenses | 49.6M | 14.3M | 30.8M | 24.1M | 25.4M |
| Operating Income (EBIT) | (47.1M) | (14.2M) | (28.5M) | (24.1M) | (25.4M) |
| Non-Operating | |||||
| Interest Income | 219.9K | 72.0K | 12.0K | 22.8K | 2.1K |
| Interest Expense | — | — | — | — | 2.1K |
| Net Interest Income | 219.9K | 72.0K | 12.0K | 22.8K | 2.0K |
| Other Non-Op Income/Expense | (5.8M) | (8.2M) | 1.4M | 3.4M | 17.0K |
| Non-Operating Income (excl Interest) | 5.1M | — | — | 22.6K | (15.0K) |
| EBT (Pre-Tax Income) | (52.9M) | (22.4M) | (27.0M) | (20.7M) | (25.4M) |
| Income Tax Expense | (1.9M) | (1.7M) | (271.0K) | (271.1K) | (368.0K) |
| Bottom Line | |||||
| Net Income | (50.7M) | (20.7M) | (26.8M) | (20.5M) | (25.0M) |
| Earnings from Cont. Ops | (51.0M) | (20.7M) | (26.8M) | (20.5M) | (25.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (50.7M) | (20.7M) | (26.8M) | (20.5M) | (25.0M) |
| Per Share | |||||
| Basic EPS | ($47.70) | ($18.90) | ($55.00) | ($55.00) | ($95.00) |
| Diluted EPS | ($47.70) | ($18.90) | ($55.00) | ($55.00) | ($95.00) |
| Revenue Per Share | $0.81 | $0.04 | $4.81 | $0.00 | $0.04 |
| Shares | |||||
| Basic Shares Outstanding | 3.1M | 1.1M | 479600 | 368600 | 265000 |
| Diluted Shares Outstanding | 3.1M | 1.1M | 479600 | 368600 | 265000 |
| Profitability Metrics | |||||
| EBITDA | (45.2M) | (13.3M) | (26.6M) | (22.3M) | (23.5M) |
| D&A | 1.9M | 934.0K | 1.9M | 1.9M | 1.9M |
| EBIT | (47.1M) | (14.2M) | (28.5M) | (24.1M) | (25.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025